The IAS–USA Annual Update on HIV Management in Chicago, Illinois

The IAS–USA Annual Update on HIV Management in Chicago, Illinois

Registration Details

  • In-Person Registration: $70.00 (USD)
  • In-Person Registration ends: Thursday, May 9, 2024
  • In-Person Fellows: $25.00 (USD)
  • In-Person Fellows ends: Thursday, May 9, 2024


Constance A. Benson, MD
University of California San Diego
Paul A. Volberding, MD
University of California San Francisco


Judith A. Aberg, MD
Icahn School of Medicine at Mount Sinai 
Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Susan P. Buchbinder, MD
San Francisco Department of Public Health
Eric S. Daar, MD
University of California Los Angeles
Steven C. Johnson, MD
University of Colorado School of Medicine
Suman Srinivasa, MD, MS
Harvard Medical School
Darcy A. Wooten, MD
University of California San Diego

May 16, 2024

8:30 AM - 3:45 PM CT


Loyola University of Chicago
Quinlan Life Science Building
1050 W Sheridan Road
United States


Last Modified: Feb 13, 2024 @ 4:57 PM

Program Description

Join us for the highly anticipated and dynamic IAS–USA annual course in Chicago, Illinois, for the most current and clinically relevant information in HIV care. Don’t miss out on the opportunity to engage with faculty and peers in person and to stay at the forefront of what’s new in HIV management. This live course will be in person at the Loyola University of Chicago, and there will NOT be a simultaneous virtual component for this course.

This in-person course will focus on recent advances in HIV medicine, including updates from the Conference on Retroviruses and Opportunistic Infections (CROI) 2024; In Case You Missed It, including information recently published, or presented within the last year at other major HIV conferences; routine and special immunizations in people with HIV; preexposure prophylaxis (PrEP), including doxy-PEP; aging and cardiovascular disease risk, including an overview of the implications of the REPRIEVE study; and a case-based panel discussion on antiretroviral therapy. This course will also highlight the emerging data around the use of glucagon-like peptide 1 (GLP-1) agonist drugs in individuals with HIV, including potential applications in diabetes, weight loss, substance use disorders, and other comorbidities.

We remain committed to closely monitoring the evolving state of the pandemic. We will ensure that our vaccination policy and mask guidelines align with the circumstances leading up to the course.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
  • Implement updated primary care recommendations, including special and routine vaccinations
  • Integrate findings from the REPRIEVE trial into the treatment plans of adults with HIV
  • Describe the current research of GLP-1 agonist therapy for people with HIV
  • Identify the challenges of hypertension and cardiometabolic complications in people on antiretroviral therapy

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits

Nursing Credits

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.